title: IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL).
abstract: Recent studies have demonstrated that rodent tumour cells engineered to secrete a variety of cytokines, or to express foreign antigens, MHC molecules or co-stimulatory molecules, are rejected by syngeneic animals. These observations have led to the initiation of a number of clinical trials using genetically modified tumour cells, to attempt to stimulate a patient anti-tumour immune response. In this study, a protocol has been developed to test in vitro the specific cytotoxic anti-tumour response generated from melanoma patient lymphocytes. The results showed that IL-12 in combination with IL-2 enhanced the autologous anti-melanoma CTL response, whereas B7.1 antigen expression on tumour cells did not increase anti-melanoma CTL generation. This method could be used to design more appropriate genetically modified tumour vaccines.
authors.affiliation: CRC Centre for Cell and Molecular Biology, Chester Beatty Laboratories, London, UK.
authors.forename: D
authors.initials: D
authors.lastname: De Wit
authors.forename: C L
authors.initials: CL
authors.lastname: Flemming
authors.forename: J D
authors.initials: JD
authors.lastname: Harris
authors.forename: K J
authors.initials: KJ
authors.lastname: Palmer
authors.forename: J S
authors.initials: JS
authors.lastname: Moore
authors.forename: M E
authors.initials: ME
authors.lastname: Gore
authors.forename: M K
authors.initials: MK
authors.lastname: Collins
mesh_terms: D018122:B7-1 Antigen / Q000502:physiology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D018664:Interleukin-12 / Q000494:pharmacology*; D008545:Melanoma / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D018122:B7-1 Antigen; D018664:Interleukin-12